» Authors » Viswanath Devanarayan

Viswanath Devanarayan

Explore the profile of Viswanath Devanarayan including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 57
Citations 2290
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
11.
Manning M, Hassanein M, Partridge M, Jawa V, Mora J, Ryman J, et al.
AAPS J . 2022 Jul; 24(4):81. PMID: 35821280
During biotherapeutic drug development, immunogenicity is evaluated by measuring anti-drug antibodies (ADAs). The presence and magnitude of ADA responses is assessed using a multi-tier workflow where samples are screened, confirmed,...
12.
Mirzayi C, Renson A, Zohra F, Elsafoury S, Geistlinger L, Kasselman L, et al.
Nat Med . 2021 Nov; 27(11):1885-1892. PMID: 34789871
The particularly interdisciplinary nature of human microbiome research makes the organization and reporting of results spanning epidemiology, biology, bioinformatics, translational medicine and statistics a challenge. Commonly used reporting guidelines for...
13.
Llano D, Kwok S, Devanarayan V
Front Hum Neurosci . 2021 Oct; 15:739754. PMID: 34630060
Multiple epidemiological studies have revealed an association between presbycusis and Alzheimer's Disease (AD). Unfortunately, the neurobiological underpinnings of this relationship are not clear. It is possible that the two disorders...
14.
Llano D, Devanarayan V
J Alzheimers Dis . 2021 Feb; 80(1):311-319. PMID: 33523012
Background: There is intense interest in the development of blood-based biomarkers, not only that can differentiate Alzheimer's disease (AD) from controls, but that can also predict conversion from mild cognitive...
15.
Llano D, Issa L, Devanarayan P, Devanarayan V, Alzheimers Disease Neuroimaging Initiative Adni
Cells . 2020 Dec; 9(12). PMID: 33260532
Recent data have found that aging-related hearing loss (ARHL) is associated with the development of Alzheimer's Disease (AD). However, the nature of the relationship between these two disorders is not...
16.
17.
Civoli F, Kasinath A, Cai X, Wadhwa M, Exley A, Oldfield P, et al.
AAPS J . 2019 Dec; 22(1):7. PMID: 31792633
For biosimilar drug development programs, it is essential to demonstrate that there are no clinically significant differences between the proposed biosimilar therapeutic (biosimilar) and its reference product (originator). Based on...
18.
Llano D, Devanarayan P, Devanarayan V
Alzheimer Dis Assoc Disord . 2019 Jul; 33(4):307-314. PMID: 31305322
Background: Previous work has suggested that the brain and cerebrospinal fluid (CSF) levels of a neural protein involved in synaptic transmission, VGF (a noninitialism), may be altered in mild cognitive...
19.
Myler H, Gorovits B, Phillips K, Devanarayan V, Clements-Egan A, Gunn G, et al.
AAPS J . 2019 Apr; 21(4):55. PMID: 30993501
In September 2018, the American Association of Pharmaceutical Scientists (AAPS) conducted an Annual Guidance Forum on the considerations related to immunogenicity testing for therapeutic protein products. In addition to a...
20.
Devanarayan P, Devanarayan V, Llano D
J Alzheimers Dis . 2019 Feb; 68(2):537-550. PMID: 30775985
The 2018 NIA-AA research framework proposes a classification system with Amyloid-β deposition, pathologic Tau, and Neurodegeneration (ATN) for diagnosis and staging of Alzheimer's disease (AD). Data from the Alzheimer's Disease...